Proteomics International

Proteomics International Laboratories Limited (ASX:PIQ) is a medical technology company at the forefront of predictive diagnostics and bio-analytical services. The Company specialises in the area of proteomics the industrial scale study of the structure and function of proteins. Proteomics Internationals mission is to improve the quality of lives by the creation and application of innovative tools that enable the improved treatment of disease. Proteomics International is now implementing a stepped rollout of PromarkerD, its flagship diagnostic test for diabetic kidney disease, globally. Successful commercialisation of this diagnostic test is expected to bolster Proteomics revenue base. PromarkerD licensing fees and royalty...

In-vitro diagnostics,predictive diagnostics,medical prognostics,platform technology,proprietary algorithm,proteomics,diabetes management,diabetic kidney disease (dkd),asymptomatic disease,personalised medicine,precision therapy,elisa test,biosimilars / biologics drug characterisation,biomarker discovery,drug discovery,pharmacokinetic testing,proteome mapping,accredited protein analytical services,and hplc-ms

Proteomics international operates in the Medical device industry.

Proteomics international's revenue is < 1m

Proteomics international has 11 - 50 employees.